09-14-2017 09:28 AM CET - Health & Medicine
Print

Download Global Nano Chemotherapy Market and Clinical Trials Outlook 2022 Report

Press release from: Kuick Resarch

“Global Nano Chemotherapy Market and Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component. The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.

Conventional chemotherapeutic agents are distributed non-specifically in body where they affect both cancerous and normal cells and thereby it limit the dose availability with in the tumor and also results in suboptimal treatment due to excessive toxicities. To overcome the limitations of chemotherapy treatment, many more therapies has also been emerged.

The use of nanoparticles by both passive and active targeting strategies can enhance the intracellular concentration of drugs in cancer cells while avoiding the toxicity in normal cells. When the nanoparticles bind to a specific receptors and then enter the cell, usually enveloped by endosomes through receptor mediated endocytosis and thereby bypassing the recognition of P glycoprotein.

Nanomedicine has already met with success in oncology domain with various product commercially available in the market. By releasing the efficacy of nanomedicine in oncology, it increases the interest of the market players to commercialize the products in the field of nanotherapeutics and helps to increase the global market. The future of nanotherapeutics is bright and especially for the reversible cross linked nano carriers which are decorated with the cancer targeting ligands and it promote the endocytic uptake in tumor cells. The approach has the potential to overcome the drug resistance which is often with conventional chemotherapies.

For the next generation cancer nanotherapeutics, the complexity is higher which are under clinical development in terms of hybrid structures, surface physiochemical characteristics and mechanisms of delivery and action. There have been rapid advances in the nano therapeutic field in the past decade. Many of the nano carriers have been developed from which some have the great therapeutic potential. However, there remain many challenges in translating the nanoparticle drugs into the clinics.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: www.kuickresearch.com/report-global-nano-chemotherapy-mar...

Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential

Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles

Role of Nanotherapeutics in Various Diseases Treatment
3.1 Nanotherapeutics Approach for Cardiovascular Disease
3.2 Nanotherapeutics Approach for Cancer Therapy
3.3 Nanotherapeutics Approach for Diabetes Treatment
3.4 Nanotherapeutics Approach for Rheumatoid Arthritis

Chemotherapeutics Nanoformulations of Approved Drugs: Clinical Insights and Price Analysis
4.1 Abraxane (Advanced Lung, Pancreatic, Breast Cancers)
4.2 Depocyte (Lymphomtous Meningitis)
4.3 Doxil (Kaposi’s Sarcoma, Ovarian Cancer)
4.4 Marqibo (Acute Myelogenous Leukemia)
4.5 Neulasta (Chemotherapy Induced Neutropenia)
4.6 Oncospar (Acute Lymphoblastic Leukemia)
4.7 Zevalin (Non-Hodgkin Lymphoma)

Chemotherapeutics Nanoformulations in Clinical Trials: Clinical Insight and Mode of Action
5.1 MM-302 (Metastatic Breast Cancer)
5.2 Thermodox (Hepatobiliary Tumors)
5.3 CPX-351 (Acute Myelogenous Leukemia)
5.4 IHL-305 (Solid Tumor Malignancy)
5.5 MM-398 (Metastatic Pancreatic Cancer)
5.6 BIND-014 (Metastatic Prostate Cancer)
5.7 NK-012 (Solid Tumor Malignancy)
5.8 CRLX-101 (Solid Tumor Malignancy and Rectal Cancer)

Global Market Nanotherapeutics Outlook
6.1 Market Scenario of Nanotherapeutics
6.2 Market Size of Nanomedicine

Cancer Nanotherapeutics Market Revenue
7.1 Sales of Nano Chemotherapeutic Drugs
7.2 Top Nanotherapeutics Companies Revenue
7.3 Global Cancer Nanomedicine Clinical Pipeline Overview

Global Nano Chemotherapeutics Market Dynamics
8.1 Favorable Parameters
8.2 Challenges to the Market Growth

Future Perceptive of Nano Chemotherapeutics

Competitive Landscape
10.1 Ablynx
10.2 AMAG
10.3 Amgen
10.4 Celgene
10.5 CytImmune
10.6 Cornerstone
10.7 Delpor
10.8 Ensysce
10.9 MagForce AG
10.10 Merrimack
10.11 Nanotherapeutics
10.12 Nanobiotix
10.13 Nanospectra
10.14 Spectrum pharmaceuticals
10.15 Tarveda

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.
News-ID: 716067 • Views: 84
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: